Objective: To make a research on the prognosis factors of non-hodgkin lymphoma (NHL) cases, and discuss how to improve the prognosis as far as possible.Meth
Objective: Carfilzomib (K) is a selective proteasome inhibitor that is approved in the United States for the treatment of relapsed and refractory multiple m